NCT04977596 is a clinical trial of No intervention in Neuroendocrine Tumor of Pancreas, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04977596?

NCT04977596 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04977596?

Interventions in NCT04977596: No intervention.

What condition does NCT04977596 study?

NCT04977596 studies Neuroendocrine Tumor of Pancreas, Carcinoma, Pancreatic, CT.

Is NCT04977596 still recruiting?

NCT04977596 is currently completed. Last updated 27 July 2021.

Last reviewed 2021-07-27 · How we verify

NCT04977596

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer

Completed Last updated 27 July 2021

What this trial tests

trial testing No intervention in Neuroendocrine Tumor of Pancreas in 78 participants. Completed in 25 June 2019.

Timeline

1 January 2012

Primary endpoint
1 January 2019

25 June 2019

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	78
Start date	1 January 2012
Primary completion	1 January 2019
Estimated completion	25 June 2019
Sites	1 location across China

Drugs / interventions tested

No intervention

Conditions studied

Neuroendocrine Tumor of Pancreas — all drugs for Neuroendocrine Tumor of Pancreas →
Carcinoma, Pancreatic — all drugs for Carcinoma, Pancreatic →
CT — all drugs for CT →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Eligibility, any sex, with Neuroendocrine Tumor of Pancreas or Carcinoma, Pancreatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Imaging findings (including CT and MRI images) of both well-differentiated G3 PNET and poorly differentiated PNET were studied; 2. The CT imaging findings of G3 stage PNET and pancreatic cancer were compared to establish a Logistic regression diagnostic model, and the survival analysis of the two was compared. 3. Cox regression was used to study the risk factors for survival prognosis of well-differentiated and poorly differentiated PNET based on CT image features

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Neuroendocrine Tumor of Pancreas

Currently open trials in the same condition.

NCT06472388 — Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors · Phase 2 · recruiting
NCT06148636 — A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors · EARLY_PHASE1 · active not recruiting
NCT06523582 — Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients · recruiting
NCT05037461 — Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients · NA · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04977596 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 27 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04977596.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing